Back HCV Policy & Advocacy

HCV Policy & Advocacy

AASLD 2014: 1 Million People with Hepatitis C in the U.S. Meet High Priority Criteria for Treatment

An estimated 813,000 people with diagnosed hepatitis C in the U.S. have undergone liver disease staging and meet the "highest" or "high" priority criteria for immediate treatment, according to an analysis presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. The number would be even higher if taking into account undiagnosed individuals and prisoners and others excluded from household surveys.

alt

Read more:

Obamacare Deadline Coming Up, Guide Offers Covered California Advice for HIV, HCV, PrEP

December 15 is the deadline to enroll in Affordable Care Act (ACA or "Obamacare") health plans for insurance coverage starting on January 1, 2015. Finding the right plan can be tricky for people with HIV or hepatitis C, and for those who want coverage for Truvada for pre-exposure prophylaxis (PrEP), but there are resources to help.

alt

Read more:

Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers

A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.

alt

Read more:

Gilead Announces Generic Licensing Agreements for Hepatitis C Drug Sofosbuvir

Gilead Sciences announced this week that it has granted a license to 7 generic drug companies in India to produce cheaper versions of its groundbreaking hepatitis C polymerase inhibitor sofosbuvir (Sovaldi) and its forthcoming sofosbuvir/ledipasvir coformulation for use in more than 90 developing countries.

alt

Read more:

EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies

Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX179) plus Janssen's HCV protease inhibitor simeprevir (Olysio) and ribavirin produced early sustained virological response rates of about 80% in a small study presented at the 49th EASL International Liver Congress last month in London. Another study showed that the company's HCV polymerase inhibitor candidate IDX21437 looks good in preclinical studies and is a potential once-daily partner for samatasvir in interferon-free regimens.

alt

Read more: